ELOVL2

ELOVL2 — The Final Step in DHA Synthesis

Most people know that omega-3 fatty acids protect the heart and brain, but
far fewer know that the body's ability to make its own DHA from dietary
precursors varies significantly by genetics. The ELOVL2 gene encodes
elongase-2 | An enzyme in the endoplasmic reticulum that extends the carbon
chain of long-chain polyunsaturated fatty acids by two carbon units per
catalytic cycle, the enzyme responsible for the final elongation steps
in the omega-3 pathway: converting EPA (20:5) to
DPA | Docosapentaenoic acid (22:5 n-3) — an intermediate omega-3 that accumulates
when the final step to DHA is impaired and DPA to
DHA | Docosahexaenoic acid (22:6 n-3) — the dominant omega-3 in brain and retinal
tissue, required for synaptic plasticity, visual function, and anti-inflammatory
signaling. The rs2236212 variant, located in an intron of the ELOVL2 gene,
is associated with reduced elongase activity and has measurable effects on
circulating DHA levels, liver fat accumulation, and the magnitude of response
to omega-3 supplementation.

The Mechanism

ELOVL2 is most highly expressed in the liver, where it catalyzes two sequential
elongation reactions: EPA → DPA (24:5), then DPA → TPA (24:6), which is then
desaturated and chain-shortened to DHA by the enzyme FADS2. The rs2236212 C
allele is an intronic variant that does not alter the amino acid sequence of
the protein, but appears to reduce the transcriptional output or splicing
efficiency of the ELOVL2 gene, resulting in lower effective elongase activity.
Maguolo and colleagues | Maguolo A et al. Influence of genetic variants in FADS2
and ELOVL2 genes on BMI and PUFAs homeostasis in children and adolescents with
obesity. Int J Obes, 2021
demonstrated this directly in a cohort of 1,649 obese Italian children: the
rs2236212 C allele was significantly associated with reduced enzymatic
elongation activity (p = 0.048), confirming that the genotype has a measurable
functional consequence.

The downstream result is that C-allele carriers convert EPA to DHA less
efficiently, causing EPA and DPA to accumulate at slightly higher levels while
DHA production is blunted. This creates a scenario where baseline plasma DHA
may be lower, but the precursor EPA is more readily available — which explains
the paradox seen in supplementation studies.

The Evidence

The most directly informative study is by
Alsaleh and colleagues | Alsaleh A et al. ELOVL2 gene polymorphisms are associated
with increases in plasma eicosapentaenoic and docosahexaenoic acid proportions after
fish oil supplement. Genes Nutr, 2014
who randomized 367 subjects to different fish oil doses. At the highest dose
(1.8 g/day EPA+DHA), minor C-allele carriers showed approximately 30% higher
plasma EPA and 9% higher DHA compared to GG homozygotes, with a highly
significant genotype × treatment interaction (p < 0.0001 for EPA; p = 0.004
for DHA). At baseline, however, C-allele carriers had lower DHA proportions.
This pattern — lower baseline DHA, larger supplementation response — is the
hallmark of impaired endogenous elongation that can be partially rescued by
exogenous DHA supply.

Large-scale population genetics supports this. The
CHARGE Consortium meta-analysis | Lemaitre RN et al. Genetic loci associated with
plasma phospholipid n-3 fatty acids: a meta-analysis of genome-wide association
studies from the CHARGE Consortium. PLoS Genet, 2011
of 8,866 European adults found that ELOVL2 minor alleles were associated with
higher EPA (p = 2×10⁻¹²) and DPA (p = 1×10⁻⁴³) but lower DHA (p = 1×10⁻¹⁵)
in plasma phospholipids — exactly the pattern expected from a reduction in the
EPA→DPA→DHA elongation cascade.

Beyond fatty acid composition, the rs2236212 C allele has also been linked to
metabolic consequences of impaired DHA synthesis. In a cohort of 514 obese
children,
Zusi and colleagues | Zusi C et al. Contribution of a genetic risk score to
clinical prediction of hepatic steatosis in obese children and adolescents.
Dig Liver Dis, 2019
found that rs2236212 was independently associated with a 34% higher odds of
nonalcoholic fatty liver disease (NAFLD; OR = 1.34, p = 0.047). This is
biologically plausible: DHA regulates hepatic lipid metabolism and reduces
de novo lipogenesis; impaired DHA synthesis could contribute to hepatic fat
accumulation.

Practical Implications

The key take-away for C-allele carriers — particularly CC homozygotes — is
that the body's endogenous DHA production is constrained. This means dietary
EPA (from flaxseed, chia seeds, walnuts) is a poor substitute for preformed
DHA, because the elongation step that would convert EPA to DHA is exactly
what is compromised. Preformed DHA from marine sources bypasses this
bottleneck entirely.

The Alsaleh supplementation data also suggests that C-allele carriers are
not unresponsive to omega-3s — quite the opposite. They appear to derive a
larger relative increase in EPA and DHA from supplementation, meaning
preformed DHA supplementation is both necessary and effective for this
genotype.

Interactions

ELOVL2 functions downstream of the FADS desaturases in the omega-3
pathway. The FADS1 and FADS2 enzymes (encoded by variants including
rs174547 and rs174537) perform the preceding desaturation steps, converting
alpha-linolenic acid (ALA) to EPA. C-allele carriers at rs2236212 who also
carry low-activity FADS variants face a compounded impairment across
multiple steps of the omega-3 synthesis pathway. For these individuals,
reliance on plant-based ALA is doubly ineffective — both the FADS
desaturation step and the ELOVL2 elongation step are compromised.
The ELOVL2 rs953413 variant is in linkage disequilibrium with rs2236212
in European populations and has been studied independently in relation
to sex-specific differences in DHA response to EPA supplementation.